For our investigations on the potential of a recombinant anti-GM-CSF antibody to treat psoriasis, we chose the murine model of IMQPD because this complex model closely reflects several key histopathological and pathogenic features of human plaque psoriasis, thereby satisfying the requirements for a valid psoriasis model [23]. Here, CSF2 is linked to psoriasis vulgaris.